| 1 -0.04 (-3.85%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.62 | 1-year : | 3.58 |
| Resists | First : | 2.24 | Second : | 3.06 |
| Pivot price | 1.32  |
|||
| Supports | First : | 0.91 | Second : | 0.75 |
| MAs | MA(5) : | 0.99 |
MA(20) : | 1.61 |
| MA(100) : | 6.82 |
MA(250) : | 33.36 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 6.4 |
D(3) : | 5.1 |
| RSI | RSI(14): 23.1 |
|||
| 52-week | High : | 92.75 | Low : | 0.91 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ JAGX ] has closed above bottom band by 31.2%. Bollinger Bands are 70.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 51 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.07 - 1.08 | 1.08 - 1.08 |
| Low: | 0.99 - 0.99 | 0.99 - 1 |
| Close: | 0.99 - 1 | 1 - 1.01 |
Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.
Thu, 30 Jul 2026
Jaguar Health Inc (JAGX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tue, 28 Jul 2026
Jaguar Health (JAGX) Highlights Market Potential of Neonorm Dog Amidst Challenging Valuation - GuruFocus
Tue, 28 Jul 2026
Almost 80% of Vet Oncologists Would Recommend Neonorm Dog - Stock Titan
Mon, 27 Jul 2026
Jaguar Health Inc (JAGX) Institutional Confidence - TradingKey
Mon, 27 Jul 2026
Jaguar Health, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Fri, 24 Jul 2026
Jaguar Health (NASDAQ: JAGX) puts major dilution and incentive plan votes to investors - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 52 (K) |
| Shares Short P.Month | 55 (K) |
| EPS | -695.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -38.12 |
| Profit Margin | -115.4 % |
| Operating Margin | 50.2 % |
| Return on Assets (ttm) | -35.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 815.5 % |
| Gross Profit (p.s.) | 5.12 |
| Sales Per Share | 6.02 |
| EBITDA (p.s.) | -4.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.03 |
| Price to Sales | 0.16 |
| Price to Cash Flow | -0.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|